Kangfang Biological Announces Phase II Data of PD-1/VEGF Double Antibody + Chemotherapy First-line Treatment of NSCLC

Article source: Medical Rubik's Cube Info

On September 26, Kangfang Bio-Bio announced that it will announce the first international PD-1/VEGF bi-antibody AK112 combined with chemotherapy for the first-line treatment of advanced non-small cell lung cancer in the first-line treatment of advanced non-small cell lung cancer at the 2021 CSCO conference

AK112 is independently developed by Kangfang Bio, the world's first PD-1/VEGF bispecific antibody to enter clinical research

The combination therapy of PD-1 antibody and VEGF blocker has shown strong curative effect in a variety of tumor types (such as renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma)

This multicenter, open phase II clinical study (AK112-201, NCT04736823) aims to evaluate the effectiveness and safety of AK112 combined with chemotherapy in the treatment of advanced non-small cell lung cancer

As of August 5, 2021, a total of 37 newly-treated NSCLC patients were enrolled and received AK112 combined with paclitaxel + carboplatin or pemetrexed + carboplatin

A total of 26 patients with newly treated NSCLC completed at least one post-baseline tumor assessment, including 18 non-squamous cell carcinomas and 8 squamous cell carcinomas; 12 had PD-L1 expression negative, 11 had PD-L1 expression positive, and 3 cases were unknown

The following is the clinical development strategy of AK112.

It is worth noting that on September 24, the listing application of Kangfang Bio-PD-1/CTLA-4 bispecific antibody Cadonilimab (Cadonilimab) has been accepted by the State Food and Drug Administration and has been given priority review for Treatment of recurrent or metastatic cervical cancer

In November 2020, Kangfang Biological released the phased data of Cadonilimab, showing that the objective remission rate in patients with recurrent or metastatic cervical squamous cell carcinoma reached 47.